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Summary There is no effective systemic therapy for dis-
seminated metastatic melanoma. Data suggest that endothe-
lin may play a role in pathophysiology of melanoma and that
the dual endothelin receptor antagonist bosentan may have
anti-tumor activity.
This multicenter, open-label, single-arm, prospective,
proof-of-concept study assessed the effects of bosentan
monotherapy (500 mg oral tablets, bid) on tumor response
in patients with stage IV metastatic melanoma. Patients
were treated until disease progression, death or serious
adverse event leading to premature study drug discontinu-
ation. Tumor response was assessed at 6-weekly intervals
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using the Response Evaluation Criteria in Solid Tumors
(RECIST).
Among the 35 patients included in this study with stage
IV metastatic melanoma, 21 (60%) were stage M1C, 10
(29%) stage M1B and 4 (11%) stage M1A (American Joint
Committee on Cancer [AJCC] classification). Nine patients
(26%) had received prior therapy for stage IV melanoma.
Disease stabilization was observed in 6 of the 32 patients
analyzed per protocol at week 6 with confirmatory evaluation
at week 12, 5 of whom were still stable at ≥ 24 weeks. Of
the 6 patients with disease stabilization, 2 were stage M1A, 1
was stage M1B and the remaining 3 were stage M1C. Partial
or complete response was not observed. Progressive disease
was observed in 17 (49%) patients at week 12 and in 25
(71%) patients at the end of the study (data base closure). The
most frequent adverse events were typical for the underlying
disease or known to be associated with bosentan: headache
(43%), fatigue (34%), nausea (31%), back pain (23%) and
abnormal hepatic function (23%).
Bosentan might have benefit in disease stabilization in cer-
tain patients with metastatic melanoma and deserves further
investigation in combination with other anticancer drugs.
Keywords Bosentan . Endothelin receptor . Metastatic
melanoma
Introduction
Patients with metastatic malignant melanoma have an un-
favorable prognosis. Patients with extra-pulmonary visceral
involvement, or an elevated serum lactate dehydrogenase
(LDH) have a median survival of 4–6 months and a 2-year
survival of ≤ 5% [1]. There is no effective treatment for
metastatic melanoma, as there is no evidence from ran-
domized controlled trials that any form of systemic therapy
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prolongs overall survival [2–4]. Single agent treatment with
dacarbazine (dimethyl triazeno imidazole carboxamide,
DTIC) remains the reference standard treatment for stage IV
melanoma, yet in recent Phase III prospective randomized
trials response rates were only 6.8–13% [5–7].
The present study involves a novel approach to treatment
of melanoma by antagonism of endothelin (ET) receptors
ETA and ETB. The ET system, and the ETB receptor in
particular, plays a fundamental role in the physiology of
melanocytes [8–10]. Activation of ETB receptors by ET-1
promotes proliferation of melanogenic precursor cells and
inhibits their differentiation, two characteristic features of
melanoma genesis [11]. Furthermore, ET-1 mediates ultravi-
olet light-induced melanin synthesis in human melanocytes
[12]. In melanocytes and melanoma cells, ET-1 increases
the expression of the melanoma invasion promoter MCAM
(melanoma cell adhesion molecule) while decreasing ex-
pression of the melanoma invasion suppressor E-cadherin
[13, 14]. In human melanoma, ETB receptor expression is
upregulated and the increased expression is correlated with
tumor progression [15]. Consistent with these observations,
ETB receptor blockade with BQ788 inhibits growth, causes
re-differentiation and induces cell death of human melanoma
cell lines [16].
The endothelin system may contribute to tumor growth
and progression by multiple mechanisms, including cell pro-
liferation, angiogenesis, and escape from apoptosis [17].
Bosentan, a non-peptide orally active dual ETA and ETB
receptor antagonist, inhibited melanoma cell proliferation
in vitro in all examined cell lines and in a mouse xenograft
model [18]. Bosentan reversed ET-1-induced inhibition of
apoptosis [19] and potentiated Fas ligand-mediated apopto-
sis in melanoma, as well as in colon carcinoma, and glioblas-
toma cells [19–21]. Furthermore, bosentan inhibited ET-1-
mediated angiogenesis [22]. The role of the ET system in
the pathophysiology of melanoma and the experimental data
with endothelin receptor antagonists provide the rationale to
assess bosentan in a proof-of-concept study in patients with
metastatic melanoma.
The primary objective of this study was to evaluate the
effect of bosentan on tumor response when administered
as first- or second-line therapy to patients with stage IV
metastatic melanoma. The secondary objective was to
evaluate safety and tolerability of bosentan in this patient
population.
Dose selection
Bosentan is an established treatment of pulmonary arterial
hypertension [23] and is well tolerated in this patient popu-
lation at a dose of 125 mg bid. However, the study dose was
selected to maximize potential benefit to the patient and pro-
vide a sufficient exposure to the skin to block ET receptors
and potentially inhibit tumor growth. The IC50 for bosentan
to inhibit the growth of melanoma cell lines in vitro mea-
sured by H3-thymidine incorporation is around 30 µg/ml
[18]. To attain in vivo bosentan concentrations closer to this
IC50 value, a dose of 500 mg bid was chosen. This higher
dose has been generally well tolerated in previous bosentan
trials [24].
Patients and methods
The study was performed in 5 centers in Australia. Eligible
patients were males or females ≥18 years with histologically
proven metastatic melanoma, measurable stage IV disease
according to the Response Evaluation Criteria in Solid Tu-
mors (RECIST), no evidence of central nervous metastasis
or carcinomatous meningitis, Eastern Cooperative Oncology
Group (ECOG) performance status ≤1 and a life expectancy
>12 weeks. Patients must have had no prior systemic
therapy, or failed no more than one prior course of sys-
temic therapy for metastatic melanoma. Patients could not
be included if they had: alanine aminotransferase (ALT)
and/or aspartate aminotransferase (AST) >3 times the up-
per limit of normal (ULN), or >2 times ULN and total
bilirubin >2.0 mg/dl, lactate dehydrogenase (LDH) >1.5
times ULN, systolic blood pressure <85 mmHg, chronic
heart failure New York Heart Association Class III or IV or
hemoglobin <30% the lower limit of normal.
Prohibited concomitant therapies included other therapies
for melanoma as well as cyclosporine A, tacrolimus and
glibenclamide (glyburide).
The study was conducted in full compliance with the prin-
ciples of the Declaration of Helsinki and Good Clinical Prac-
tice. The protocol was approved by the independent ethics
committee at the study sites. Voluntary written informed con-
sent was obtained from all patients prior to enrolment into
the study.
Treatment
Bosentan was administered in an open-label fashion until
disease progression, death or an adverse event leading to
study drug discontinuation occurred.
The treatment regimen consisted of 4 tablets of bosentan,
i.e., 500 mg bid administered orally. Bosentan had to be
discontinued if hepatic aminotransferases were >8 times
ULN. The dose of bosentan was reduced to 250 mg bid
if there was an increase in aminotransferases >3 and <8
times the ULN. If 1 week later, aminotransferases were as
high or further increased, the dose of bosentan was reduced
to 125 mg bid. One week later, if aminotransferases were
as high or further increased, bosentan was discontinued.
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Regardless of the aminotransaminase levels, dose increase
was not allowed after dose reduction.
Treatment evaluation
All patients underwent tumor staging that included for ex-
ample a computerized tomography (CT) scan or magnetic
resonance imaging (MRI) of the brain, chest and abdomen
within the 28 days before treatment initiation. During treat-
ment, physical examination and tumor staging by CT scans
or MRI of chest and abdomen were repeated every 6 weeks.
Laboratory tests performed at screening and at regular
interval during the study included: hemoglobin, bilirubin,
ALT, AST, LDH, alkaline phosphatase, sodium, potassium,
creatinine, and if applicable, pregnancy tests.
Safety and tolerability assessments included Adverse
Events (AEs) and Serious Adverse Events (SAEs).
Tumor biopsy specimens were obtained before treatment
from 5 patients with cutaneous lesions in order to evaluate
the gene expression levels of ETA and ETB receptors and
their ligands ET-1, ET-2 and ET-3. Specimens were cut in
half and two independent RNA isolations were performed.
Total RNA was reverse transcribed using random hexamers.
Real-time quantitative PCR was performed with an SDS
7000 system using the TaqMan r© Universal PCR Master
Mix and specific TaqMan r© Gene Expression assays (human
ETA receptor: Hs00609865 m1; ET-1: Hs00174961 m1;
ET-2: Hs00266516 m1 and ET-3: Hs00171177 m1).
For human ETB receptor, specific TaqMan r© probes
were designed: Forward 5′GGGCCACTCCGCTTTTG-3′,
Reverse 5′-CCCTTGGGCCATAAGGTCTT-3′, TaqMan r©
probe 5′-(FAM-CCGCAGAGATAATGACGCCACCCAC-
TAMRA)-3′. All reactions were multiplexed and normalized
to 18S rRNA probes and done in duplicate. All agents and
software were from Applied Biosystems, USA.
Response criteria and statistical analysis
An objective tumor response was defined as complete re-
sponse, partial response or stable disease according to the
RECIST criteria [25].
The primary efficacy endpoint for this study was the
tumor objective response rate, defined as the proportion
of patients with an objective response at week 6 and
confirmatory evaluation at week 12. The objective response
rate was primarily analyzed in the per-protocol patient set
consisting of all treated patients who had an assessment of
the primary endpoint and had no major protocol deviations
that might impact the evaluation of the primary endpoint.
The duration of response and the best overall response
were analyzed in the all-treated patient set. All efficacy
endpoints were analyzed descriptively by means of appro-
priate statistics, using proportions, Kaplan-Meier estimates,
means, medians, and standard deviations. Two-sided 95%
confidence intervals (CIs) based on the binomial exact
distribution were determined for proportions.
Safety and tolerability endpoints and the evaluation of
baseline characteristics were analyzed in the all-treated pa-
tient set.
Results
Baseline characteristics and patient disposition
Between 24 March 2003 and 31 October 2003, 35 patients
were enrolled in this proof-of concept study. Demographic
and clinical characteristics of patients at baseline are sum-
marized in Table 1.
The majority of patients had advanced disease according
to the AJCC classification (60% were stage M1C). Elevated
LDH, a marker of tumor burden, was observed in all patients.
Table 1 Baseline demographic and clinical characteristics
Total number of patients 35























Mean duration of bosentan
treatment
8.8 weeks (1.1–40.1)
Study drug discontinuation before




Withdrawal of consent 1/1
Death 1/1
AJCC: American Joint Committee on Cancer; DTIC: dacarbazine;
LDH: Lactate dehydrogenase.
∗One patient experienced at the same time an AE and disease
progression.
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Table 2 Patients with stable disease ≥ 12 weeks of treatment
Stable disease Reason for study drug
Patient Age (years)/gender AJCC stage at baseline LDH at baseline (U/l) duration (days) discontinuation
311 67/M M1A 136 193 Progressive disease
502 74/M M1A 391 >844 Not applicable
306 50/M M1B 140 210 Progressive disease
510 66/F M1C 518 116 Progressive disease
101 66/M M1C 217 173 Progressive disease
102∗ 72/F M1C 193 >800 Not applicable
∗Patient 102 was diagnosed with non-Hodgkin lymphoma at Day 844.
AJCC: American Joint Committee on Cancer; F: female; LDH: lactate dehydrogenase; M: male.
The majority of patients 28/33 (85%) had an ECOG status of
0 (data were not available for 2 patients). Lesions were pre-
dominantly in the lung, lymph nodes, liver, skin and adrenal
glands. Nine patients had received prior therapy for stage IV
melanoma. One patient, in deviation from the protocol, was
enrolled in the study despite a brain metastasis.
All 35 enrolled patients were analyzed in the all-treated
patient set, but only 32 in the per-protocol patient set. Three
patients were excluded from the per-protocol population be-
cause no tumor response evaluation was performed.
All patients received the intended dose of 500 mg bid
and only 1 patient had a dose reduction to 250 mg bid, after
124 days of treatment, due to elevated hepatic aminotrans-
ferases. The mean treatment duration was 8.8 weeks, with a
range of 1.1 to 40.1 weeks. Only 8 patients (24%) received
study drug for at least 12 weeks. A total of 25 patients pre-
maturely discontinued study drug before week 12, while 33
discontinued before week 24. The reasons for study drug
discontinuation in those patients with stable disease at 12
weeks of treatment are summarized in Table 2. The two last
patients (102 and 502) continued on study drug beyond week
24 and are undergoing long-term follow up.
Efficacy
At 12 weeks of treatment, 6 patients had stable disease (see
Table 2), resulting in an objective response rate of 18.8%
(95% CI: 7.2–36.4%) in the primary per-protocol 32-patient
set, and 17.1% (95% CI: 6.6–33.6%) in the all-treated
35-patient set. Five of them had still stable disease at 24
weeks, 5 of these 6 patients received bosentan as first-line
treatment. Of the 6 patients with disease stabilization, 2
were stage M1A, 1 was stage M1B and the remaining 3 were
stage M1C. No complete or partial response was observed.
Progressive disease was observed in 17 (49%) patients at
week 12 and in 25 (71%) patients at the end of the study.
The best overall response (best response from the start
of treatment until progressive disease) was stable disease in
12 patients, i.e., 37.5% (95% CI: 19.1–52.2%) in the per-
protocol set and 34.3% in the all-treated set. The mean dura-
tion of stable disease in these patients was 144.5 days (95%
CI: 86–210 days).
At the time of last follow-up (July 2005), 2 patients
(102 and 502) had stable disease for more than 800 days
(26 months) and were still receiving bosentan. Patient 102
had cutaneous and abdominal lymph node metastases at en-
rolment. The cutaneous metastasis was excised in accordance
with protocol for endothelin receptor analysis. Biopsy of the
abdominal lymphadenopathy at day 844 showed follicular
non-Hodgkin lymphoma. No further metastatic melanoma
has developed. The size of the target lesions (lymph nodes)
over treatment time for patient 502 is plotted in Fig. 1. At 26
months, lymph node size had decreased by more than 20%.
The ECOG score could be analyzed in 30 of the 35 patients in
the all-treated set. At baseline, 26 of these 30 patients had an
ECOG score of 0, and 4 patients had a score of 1. The overall
ECOG score did not change in 18 (60%) patients, worsened
in 11 (37%) patients and improved in 1 (3%) patient.
Seven patients (20%) died due to the underlying disease.
One patient died while still being treated with bosentan,
while the other 6 died after study drug discontinuation for
progressive disease. None of the deaths was considered by














0 200 400 600 800
Time (day)
Fig. 1 Lymph node size (n = 3) over time as measured by CT scan
(patient 502)
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28 patients, censored survival at the end of the study ranged
from 22 to 363 days.
Tumor biopsy results
The RNA analysis from the 5 biopsy specimens showed
that ETA receptor gene expression was homogeneously low,
in contrast to high ETB receptor gene expression, although
large differences in ETB receptor expression levels between
specimens were observed. Within the same biopsy speci-
men, ETB receptor expression was at least 100- and up to
1000-fold higher than ETA receptor expression. ET-1 was
the predominantly expressed ligand and showed similar ex-
pression levels in all samples.
Safety and tolerability
A total of 20 SAEs were reported in 10 (29%) patients. Those
considered by the investigators to be related to study drug
were: abnormal hepatic function in 4 patients, elevation of
alkaline phosphatase in 2 patients and jaundice in 1 patient.
Of the total 210 AEs reported in 34 patients, 73 were
considered to be related to study drug according to the
investigators. The most frequent AEs were headache, fa-
tigue, nausea, back pain, and abnormal hepatic function
(Table 3). AEs leading to drug discontinuation were observed
in 7 (20%) patients: 5 for abnormal hepatic function, 1 for
elevated alkaline phosphatase, 1 for hemorrhagic stroke, and
1 for weakness of an arm due to a brain metastasis. One of
these patients had, as well, progressive disease at the time of
study drug discontinuation.
Elevations in hepatic enzymes were observed in 12 pa-
tients. In 4 patients, modest increases not exceeding 3 times
ULN were observed for a single hepatic enzyme. The re-
maining 8 (23%) patients had aminotransferases > 3 times
the ULN with or without increase of other liver enzymes.
They were reported as an AE leading to study drug discon-




Any 210 34 97
Related to study drug∗ 73 24 69






Back pain 8 23
Abnormal hepatic function 8 23
∗According to the investigator. SAEs: serious adverse events.
tinuation in 5 patients and led to halving the bosentan dose
to 250 mg bid in 1 patient.
Discussion
Administration of bosentan to patients with stage IV
metastatic melanoma resulted in stable disease in 6 of 35
patients at week 12 of treatment, and in 5 of 35 patients at
week 24 or later. Five of these 6 patients received bosen-
tan as first-line therapy. No patients experienced complete
or partial response. Progressive disease was observed in 17
(49%) patients at week 12 and in 25 (71%) patients at the
end of the study.
Disease stabilization in 2 patients treated by bosentan for
more than 26 months is intriguing, but is also consistent with
the natural history of melanoma in some individuals.
The profile of AEs was consistent with that associated
with the use of bosentan and with the nature of the underlying
disease. Overall, the dose of 500 mg bid was well tolerated in
this patient population with stage IV metastatic melanoma.
Consistent with the fact that a larger dose of bosentan was
used in this trial, there was a significantly higher incidence
of increased aminotransferases compared to the lower doses
of 125 mg bid given to patients with pulmonary arterial
hypertension.
Conclusions
This study shows that bosentan administered at a dose of
500 mg bid was well tolerated in patients with metastatic
melanoma without any unexpected adverse event.
The results of this proof-of-concept clinical study sug-
gest that bosentan might have benefit in disease stabilization
in this patient population. The potential role of endothelin
receptor antagonists such as bosentan in the treatment of pa-
tients with metastatic melanoma should be further assessed
in randomized controlled studies; for example, in combina-
tion with other anticancer drugs.
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